Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine
Authors' conclusion
Selected intermediate-risk PTC patients managed without adjuvant RAI had excellent mid-term outcomes, supporting a risk-adapted de-escalation strategy.
Study context
- Population
- Adults (≥18 years) with ATA 2015 intermediate-risk papillary thyroid carcinoma (PTC) treated with TT or thyroid lobectomy (TL), with/without lymph node dissection, managed without adjuvant radioactive iodine (RAI), followed ≥1 year; 84.8% women, mean age 40.2 ± 13.3 years
- Participants
- 99 adults
- Outcome
- Response to therapy by ATA 2015 dynamic risk stratification
- Follow-up
- Median 4.8 years
Main finding
As reported in the abstract
Response to therapy (ATA 2015 dynamic risk stratification)
Excellent response
67
67.7%
Indeterminate response
32
32.3%
Observational data: associations, not effects.
Further findings
ATA 2025 recurrence-risk reclassification
- Low risk
- 3 (3.0%)
- Low-intermediate
- 39 (39.4%)
- High-intermediate
- 52 (52.5%)
- High risk
- 5 (5.1%)
Pathological features
- Microscopic extrathyroidal extension
- 51 (51.5%)
- Lymph node metastases
- 37 (37.4%)
- Extranodal extension
- 4 (4.0%)
Original publication
Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine. Clin Endocrinol (Oxf). Published 19 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →